Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.32 |
| ▸ | PGR | P06401 | 3/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6413864 | 0.71 | CA1 (0.39) | FABP4CA1CA2MMP1MMP2 | |
| SCHEMBL5887533 | 0.70 | CA1 (0.42) | FABP4CA1CA2MMP1MMP2 | |
| SCHEMBL5887535 | 0.65 | MAPT (0.46) | FABP4CA1CA2MMP1MMP2 | |
| SCHEMBL7937672 | 0.60 | FABP4 (0.36) | FABP4CA1CA2MMP1MMP2 | |
| SCHEMBL4746886 | 0.60 | NR3C1 (0.36) | FABP4CA1CA2MMP1MMP2 | |
| SCHEMBL6414538 | 0.60 | FABP4 (0.51) | FABP4CA1CA2MMP1MMP2 | |
| SCHEMBL7513482 | 0.59 | CA12 (0.41) | FABP4CA1CA2MMP1MMP2 | |
| SCHEMBL14080720 | 0.58 | CNR2 (0.41) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL3687291 | 0.58 | L3MBTL1 (0.61) | FABP4CA1CA2MMP1MMP2 | |
| SCHEMBL7930818 | 0.57 | CA1 (0.58) | FABP4CA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276444-A1 | Porphyrin-polyamine conjugates for cancer therapy | PROGEN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7026347-B2 | Porphyrin-polyamine conjugates for cancer therapy | CELLGATE, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040152687-A1 | Porphyrin-polyamine conjugates for cancer therapy | CELLGATE, INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276444-A1 | Porphyrin-polyamine conjugates for cancer therapy | SRM, PAICS, FOLH1 | FABP4 4568/4885CA1 3732/4885CA2 4274/4885 |
| US-20040152687-A1 | Porphyrin-polyamine conjugates for cancer therapy | SRM, PAICS, FOLH1 | FABP4 4568/4885CA1 3732/4885CA2 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.